Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts

[1]  Clive G. Wilson,et al.  Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  P. Macheras.  On an Unphysical Hypothesis of Bateman Equation and its Implications for Pharmacokinetics , 2019, Pharmaceutical Research.

[3]  Cordula Stillhart,et al.  PBPK Absorption Modeling: Establishing the In Vitro–In Vivo Link—Industry Perspective , 2019, The AAPS Journal.

[4]  G. Melagraki,et al.  A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  Harvey Wong,et al.  Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models , 2017, Pharmaceutics.

[6]  E. Giralt,et al.  Jumping Hurdles: Peptides Able To Overcome Biological Barriers. , 2017, Accounts of chemical research.

[7]  R. Upton,et al.  A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption—Part II: Gastrointestinal Transit Time , 2016, The AAPS Journal.

[8]  P. Iranpour,et al.  Altered Doppler flow patterns in cirrhosis patients: an overview , 2015, Ultrasonography.

[9]  V. Karalis,et al.  A non-binary biopharmaceutical classification of drugs: the ABΓ system. , 2014, International journal of pharmaceutics.

[10]  V. Karalis,et al.  Keeping a critical eye on the science and the regulation of oral drug absorption: a review. , 2013, Journal of pharmaceutical sciences.

[11]  William H. Press,et al.  Numerical Recipes 3rd Edition: The Art of Scientific Computing , 2007 .

[12]  Panos Macheras,et al.  Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples , 2004, Pharmaceutical Research.

[13]  Sarfaraz K. Niazi.  Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2004, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition.

[14]  A. Dokoumetzidis,et al.  On the use of partial AUC as an early exposure metric. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[16]  A. Dokoumetzidis,et al.  An alternative method for the estimation of the terminal slope when a few data points are available. , 1999, Journal of pharmaceutical sciences.

[17]  T. Kararli.  Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[18]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[19]  P. Macheras,et al.  The Cutoff Time Point of the Partial Area Method for Assessment of Rate of Absorption in Bioequivalence Studies , 1994, Pharmaceutical Research.

[20]  E. R. Garrett.  The Bateman function revisited: A critical reevaluation of the quantitative expressions to characterize concentrations in the one compartment body model as a function of time with first-order invasion and first-order elimination , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[21]  Mei-ling Chen.  An Alternative Approach for Assessment of Rate of Absorption in Bioequivalence Studies , 1992, Pharmaceutical Research.

[22]  A. Parr,et al.  Gastrointestinal Behavior of Orally Administered Radiolabeled Erythromycin Pellets in Man as Determined by Gamma Scintigraphy , 1990, Journal of clinical pharmacology.

[23]  J. Graybill,et al.  Pharmacokinetics of itraconazole following oral administration to normal volunteers , 1988, Antimicrobial Agents and Chemotherapy.

[24]  J. Wagner,et al.  Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships. , 1987, Biopharmaceutics & drug disposition.

[25]  G. Arfken.  Mathematical Methods for Physicists , 1967 .

[26]  F. Kesisoglou,et al.  Physiologically Based Oral Absorption Modelling to Study Gut-Level Drug Interactions. , 2018, Journal of pharmaceutical sciences.

[27]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[28]  Malcolm Rowland,et al.  Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications , 1980 .

[29]  Sarfaraz K Niazi.  Textbook of biopharmaceutics and clinical pharmacokinetics , 1979 .

[30]  F. H. Dost,et al.  Der Blutspiegel : Kinetik der Konzentrationsabläufe in der Kreislaufflüssigkeit , 1953 .